Heir Gary, Karolchek Scott, Kalladka Mythili, Vishwanath Archana, Gomes Julyana, Khatri Raashi, Nasri Cibele, Eliav Eli, Ananthan Sowmya
Department of Diagnostic Sciences, Division of Orofacial Pain, University of Medicine and Dentistry of New Jersey, Newark, NJ, USA.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Apr;105(4):466-9. doi: 10.1016/j.tripleo.2007.09.030.
The objective of this study was to evaluate the effect of topical medications as a single treatment or in combination with systemic medications in the treatment of orofacial neuropathic pain conditions.
A retrospective chart review of 39 patients treated for orofacial neuropathic pain at the Orofacial Pain Clinic in the New Jersey Dental School was performed. In line with the treatment selection, the subjects were divided into 3 groups: topical medications only (n = 12), systemic medications only (n = 10), and a combination of both (n = 17).
The starting pain level as expressed in pain Visual Analog Scale for the 3 groups was significantly different. The combined treatment group baseline pain level (7.5 +/- 0.403 SEM; P = .0015) and the systemic treatment only group pain level (8.6 +/- 0.611 SEM; P = .0375) was significantly elevated compared to the topical only group (6.1 +/- 0.716 SEM; P = .1057). Following treatment, pain level was significantly reduced in all 3 groups. The combined group had the highest pain relief (52.0 +/- 6.676 SEM % reduction; P < .0001) followed by the systemic-only group (40.6 +/- 9.727 SEM % reduction; P = .0029) and the topicals-only group (40.9 +/- 10.775 SEM% reduction; P = .0048). The time taken for the topical treatment only to act was significantly shorter (3 weeks +/- 0.479 SEM; P = .0015) when compared with the systemic-only (4 weeks +/- 0.772 SEM; P = .3629) and the combined group (5.5 weeks +/- 0.912 SEM; P = .1738).
Topical medication as single treatment or in combination with systemic medications can reduce orofacial neuropathic pain severity. Further prospective research should be performed to validate this treatment option.
本研究的目的是评估局部用药作为单一治疗方法或与全身用药联合使用在治疗口面部神经性疼痛疾病中的效果。
对新泽西牙科学院口面部疼痛诊所治疗的39例口面部神经性疼痛患者进行了回顾性病历审查。根据治疗选择,将受试者分为3组:仅局部用药组(n = 12)、仅全身用药组(n = 10)和两者联合用药组(n = 17)。
3组患者疼痛视觉模拟量表所表达的起始疼痛水平有显著差异。与仅局部用药组(6.1±0.716标准误;P = 0.1057)相比,联合治疗组基线疼痛水平(7.5±0.403标准误;P = 0.0015)和仅全身治疗组疼痛水平(8.6±0.611标准误;P = 0.0375)显著升高。治疗后,所有3组的疼痛水平均显著降低。联合组疼痛缓解程度最高(降低52.0±6.676标准误%;P < 0.0001),其次是仅全身用药组(降低40.6±9.727标准误%;P = 0.0029)和仅局部用药组(降低40.9±10.775标准误%;P = 0.0048)。仅局部治疗起效所需时间(3周±0.479标准误;P = 0.0015)与仅全身治疗组(4周±0.772标准误;P = 0.3629)和联合组(5.5周±0.912标准误;P = 0.1738)相比显著更短。
局部用药作为单一治疗方法或与全身用药联合使用可降低口面部神经性疼痛的严重程度。应进行进一步的前瞻性研究以验证这种治疗选择。